| pubmed-article:9886603 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9886603 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9886603 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:9886603 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:9886603 | lifeskim:mentions | umls-concept:C1704272 | lld:lifeskim |
| pubmed-article:9886603 | lifeskim:mentions | umls-concept:C0079633 | lld:lifeskim |
| pubmed-article:9886603 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:9886603 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9886603 | pubmed:dateCreated | 1999-2-9 | lld:pubmed |
| pubmed-article:9886603 | pubmed:abstractText | Using arbitrarily primed polymerase chain reaction (AP-PCR) ribonucleic acid (RNA) fingerprinting, we discovered a messenger RNA (mRNA) that encoded the cytokine interleukin-8 (IL-8) that was up-regulated in the peripheral blood leukocytes (PBLs) of patients with metastatic prostate cancer (CaP) compared with similar cells from healthy individuals. We compared the total prostate-specific antigen (PSA) levels, the free/total (f/t) PSA ratios, and the immunoreactive IL-8 serum concentrations in patients with either biopsy-confirmed benign prostatic hyperplasia (BPH) or CaP. | lld:pubmed |
| pubmed-article:9886603 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9886603 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9886603 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9886603 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9886603 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9886603 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9886603 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9886603 | pubmed:issn | 0090-4295 | lld:pubmed |
| pubmed-article:9886603 | pubmed:author | pubmed-author:VeltriR WRW | lld:pubmed |
| pubmed-article:9886603 | pubmed:author | pubmed-author:NgAA | lld:pubmed |
| pubmed-article:9886603 | pubmed:author | pubmed-author:MillerM CMC | lld:pubmed |
| pubmed-article:9886603 | pubmed:author | pubmed-author:VessellaR LRL | lld:pubmed |
| pubmed-article:9886603 | pubmed:author | pubmed-author:WrightG LGLJr | lld:pubmed |
| pubmed-article:9886603 | pubmed:author | pubmed-author:MarleyG MGM | lld:pubmed |
| pubmed-article:9886603 | pubmed:author | pubmed-author:RalphDD | lld:pubmed |
| pubmed-article:9886603 | pubmed:author | pubmed-author:ZhaiMM | lld:pubmed |
| pubmed-article:9886603 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9886603 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:9886603 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9886603 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9886603 | pubmed:pagination | 139-47 | lld:pubmed |
| pubmed-article:9886603 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:meshHeading | pubmed-meshheading:9886603-... | lld:pubmed |
| pubmed-article:9886603 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:9886603 | pubmed:articleTitle | Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. | lld:pubmed |
| pubmed-article:9886603 | pubmed:affiliation | UroScience Group, UroCor, Inc., Oklahoma City, Oklahoma 73104, USA. | lld:pubmed |
| pubmed-article:9886603 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9886603 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:9886603 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9886603 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9886603 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9886603 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9886603 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9886603 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9886603 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9886603 | lld:pubmed |
